PRTA241220P5000
- 0.10
- 0.000.00%
Prothena Newsroom
H.C. Wainwright Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $48
Leerink Partners Maintains Prothena(PRTA.US) With Buy Rating, Cuts Target Price to $40
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Prothena Price Target Cut to $48.00/Share From $84.00 by HC Wainwright & Co.
Chardan Capital Initiates Coverage On Prothena Corp With Buy Rating, Announces Price Target of $40
Prothena Stock Gains 38% After Parkinson's Treatment Shows Potential Benefits
Prothena Stock Soars Despite Study Miss
Prothena Up Over 43%, On Pace for Largest Percent Increase Since September 2022 -- Data Talk
Express News | B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $22
RBC Sees Justification for Prothena Rebound After Study Miss
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Express News | Prothena Corporation PLC : Oppenheimer Cuts Target Price to $58 From $62
Express News | Prothena Shares Are Trading Higher After the Phase IIb Prasinezumab Study Showed Potential in Early Parkinson's Disease
Prothena Says Study Evaluating Prasinezumab in Early-Stage Parkinson's Disease Missed Primary Endpoint
Express News | Roche’s Phase Iib Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
We Think Prothena (NASDAQ:PRTA) Can Afford To Drive Business Growth
Top Premarket Decliners
Oppenheimer Maintains Prothena(PRTA.US) With Buy Rating, Maintains Target Price $62